NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

NeuroSense Therapeutics (NASDAQ: NRSN) received Japanese Patent 7857044 for PrimeC, its lead ALS drug candidate, extending composition and formulation protection in Japan through 2042, subject to standard terms and potential extensions.

Rhea-AI Summary

NeuroSense Therapeutics (NASDAQ: NRSN) received Japanese Patent 7857044 for PrimeC, its lead ALS drug candidate, extending composition and formulation protection in Japan through 2042, subject to standard terms and potential extensions.

The patent covers PrimeC’s unique synchronized delivery of celecoxib and ciprofloxacin, supports a long-term commercialization strategy in a key market, and complements recent U.S., Australia, and Brazil patents. PrimeC is designed to modulate neuroinflammation, iron dysregulation, autophagy, and miRNA pathways, and showed clinical, biomarker, and survival benefits in the Phase 2b PARADIGM study. NeuroSense has FDA clearance and is preparing the pivotal Phase 3 PARAGON trial.

Positive

• Japanese patent 7857044 grants PrimeC protection in Japan through 2042
• Patent covers 17 claims on PrimeC’s composition, formulation, and manufacturing
• Japan protection adds to U.S., Australia, and Brazil patents for PrimeC
• PrimeC showed clinical, biomarker, and survival benefits in Phase 2b PARADIGM
• FDA clearance obtained to proceed to Phase 3 pivotal PARAGON study
• Patent supports long-term commercialization strategy in a key pharmaceutical market

Negative

• None.

Argus Jun 9 session

+1.12% close to close 1.3x rel. volume Open Argus

Details

News Market Reaction – NRSN

On Jun 9, the day this news came out, NRSN closed 1.12% above the previous close.

Data tracked by StockTitan Argus for the Jun 9 session.

Key Figures

Japanese patent term: Through 2042 Patent claims: 17 claims Phase 2b study: PARADIGM +5 more

Japanese patent term

Through 2042

Patent 7857044 covering PrimeC composition and process

Patent claims

17 claims

Japanese patent covering PrimeC formulation and manufacturing

Phase 2b study

PARADIGM

PrimeC ALS trial with clinical, biomarker and survival benefit

Pivotal trial phase

Phase 3

Planned PARAGON ALS study for PrimeC

Shelf capacity

$150,000,000

Form F-3 base shelf registration

ATM program

$6,525,000

Capital on Demand ATM under F-3 shelf

2025 net loss

$11.125M

Full-year 2025 financial results

Year-end cash

$0.2M

Cash balance at Dec 31, 2025

Historical Context

5 past events · Latest: Apr 28

5 events

1. Apr 28

   Insider PIPE financing

   24h Move

   +7.8%

   Insider-led PIPE of 750,000 shares at a premium to prior close.

2. Apr 06

   Brazil patent grant

   24h Move

   -8.2%

   Brazilian patent through October 2042 expanding PrimeC composition protection.

3. Mar 31

   2025 results update

   24h Move

   +3.3%

   Year-end results with strong ALS data but cash of $0.2M and $11.125M loss.

4. Mar 24

   Regulatory milestones

   24h Move

   -1.5%

   Regulatory progress, strengthened data package, and upcoming Alzheimer’s readout.

5. Mar 18

   Conference data update

   24h Move

   -5.4%

   New PrimeC clinical and biomarker data presented at AD/PD 2026 conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

amyotrophic lateral sclerosis, neuroinflammation, autophagy, miRNA, +4 more

8 terms

amyotrophic lateral sclerosis medical

"lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS)."

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

neuroinflammation medical

"designed to modulate multiple disease-relevant mechanisms, including neuroinflammation, iron dysregulation,"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

autophagy medical

"disease-relevant mechanisms, including neuroinflammation, iron dysregulation, autophagy, and miRNA pathways."

Autophagy is a natural cellular process where cells break down and recycle damaged parts and unwanted material, like a house cleaning system that removes clutter to keep things running smoothly. For investors, autophagy matters because many drugs and therapies aim to boost, inhibit, or redirect this process to treat diseases; success or failure in manipulating autophagy can affect the commercial prospects and valuation of biotech companies.

miRNA medical

"iron dysregulation, autophagy, and miRNA pathways."

MicroRNA (miRNA) are short, naturally occurring RNA molecules that control how much of a given protein a cell makes, acting like tiny switches or volume knobs that turn gene activity up or down. They matter to investors because miRNA patterns can signal disease, be used as biomarkers for diagnostics, or become targets for new therapies, all of which influence the value and risk of biotech and healthcare investments. Tracking advances in miRNA research helps evaluate potential market size and clinical feasibility for related products.

extended-release formulation medical

"reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon,"

An extended-release formulation is a medicine designed to release its active ingredient slowly over an extended period instead of all at once, like a timed sprinkler that waters a lawn gradually rather than flooding it. For investors, it matters because this design can improve patient convenience and adherence, support premium pricing, extend commercial life versus immediate-release versions, and create different regulatory and competitive dynamics that affect sales and profitability.

Phase 3 medical

"advance PrimeC toward a pivotal Phase 3 clinical trial."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

Phase 2b medical

"PrimeC has demonstrated consistent clinical, biomarker, and survival benefit in the Phase 2b PARADIGM study,"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

biomarker medical

"PrimeC has demonstrated consistent clinical, biomarker, and survival benefit in the Phase 2b"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents

CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Japan Patent Office has issued a Japanese Patent 7857044 covering the Company's lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS).

The patent, entitled "Compositions comprising ciprofloxacin and celecoxib," includes 17 claims and provides protection through 2042 for the unique formulation and manufacturing process of PrimeC, including its synchronized delivery profile of celecoxib and ciprofloxacin, designed to target multiple key mechanisms underlying ALS progression.

"This patent grant further strengthens our global intellectual property estate around PrimeC and reinforces the novelty of our synchronized extended-release formulation," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Japan is a key pharmaceutical market, and this patent further supports our long-term commercialization strategy as we advance PrimeC toward a pivotal Phase 3 clinical trial."

The patent is part of NeuroSense's broader global IP portfolio protecting both the composition and formulation of PrimeC, which is designed to modulate multiple disease-relevant mechanisms, including neuroinflammation, iron dysregulation, autophagy, and miRNA pathways.

PrimeC has demonstrated consistent clinical, biomarker, and survival benefit in the Phase 2b PARADIGM study, including a significant survival benefit in extended follow-up analyses. The Company has received FDA's clearance to proceed and is preparing for initiation of a Phase 3 pivotal study (PARAGON).

The Japanese patent is expected to provide long-term protection for PrimeC's proprietary formulation in a key strategic market, subject to standard terms and potential extensions.

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company's lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has generated compelling clinical data from its Phase 2b PARADIGM study in ALS, demonstrating meaningful slowing of disease progression. The Company also reported significant biological activity across multiple biomarkers associated with ALS, including microRNAs, supporting PrimeC's multi-target mechanism of action. Notably, long-term follow-up data indicated a meaningful survival benefit, representing a potentially important advancement in the treatment of ALS.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pivotal Phase 3 clinical trial (PARAGON) in ALS, which is expected to enroll approximately 300 participants, primarily in the United States.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements, including statements regarding the benefits of the Japanese patent, development, regulatory progress and potential commercialization of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding the benefits of the Japanese patent; outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-therapeutics-receives-japanese-patent-grant-for-primec-novel-composition-302795240.html

SOURCE NeuroSense

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NeuroSense Therapeutics (NRSN) announce on June 9, 2026 about PrimeC in Japan?

NeuroSense announced that the Japan Patent Office granted Patent 7857044 for PrimeC, protecting its novel composition and formulation through 2042. According to NeuroSense, this strengthens its global IP portfolio and supports long-term commercialization in a key pharmaceutical market.

How long does the new Japanese patent protect NeuroSense’s PrimeC (NRSN) for ALS?

The Japanese patent for PrimeC provides protection through 2042, subject to standard terms and potential extensions. According to NeuroSense, it covers the unique formulation, manufacturing process, and synchronized delivery profile of celecoxib and ciprofloxacin in Japan.

What clinical results has PrimeC shown before NeuroSense’s Phase 3 PARAGON trial (NRSN)?

PrimeC demonstrated consistent clinical, biomarker, and survival benefits in the Phase 2b PARADIGM study. According to NeuroSense, extended follow-up showed significant survival benefit, supporting advancement of PrimeC into the pivotal Phase 3 PARAGON ALS trial.

How does the Japanese patent grant impact NeuroSense Therapeutics’ ALS strategy (NRSN)?

The Japanese patent is expected to support NeuroSense’s long-term commercialization strategy for PrimeC in a key market. According to NeuroSense, it reinforces the novelty of the synchronized extended-release formulation and complements existing patents in the U.S., Australia, and Brazil.

What mechanisms does PrimeC target in treating ALS according to NeuroSense (NRSN)?

PrimeC is designed to modulate multiple disease-relevant mechanisms in ALS, including neuroinflammation, iron dysregulation, autophagy, and miRNA pathways. According to NeuroSense, this multi-target approach underlies its synchronized celecoxib and ciprofloxacin formulation and clinical development strategy.

Has the FDA cleared NeuroSense Therapeutics (NRSN) to start the Phase 3 PARAGON ALS trial?

Yes, NeuroSense has received FDA clearance to proceed with the Phase 3 pivotal PARAGON study of PrimeC. According to NeuroSense, the company is preparing to initiate this trial following positive Phase 2b PARADIGM results and global patent strengthening.